About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 3NCT00644969

Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder

Study will determine whether patients with schizophrenia or schizoaffective disorder can be helped to quit smoking safely while using varenicline and receiving smoking cessation counseling.

Lead sponsor: Pfizer•9 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Pfizer

This is a safety study.

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Have a diagnosis (using the SCID-I/P at screening visit) of schizophrenia or schizoaffective disorder and judged to be stable (without hospitalization or acute exacerbation and functioning in society) on psychiatric treatment for at least the past 6 month.
•Current cigarette smokers (at least 15/day during the past year with no period of abstinence greater than 3 months in the past year) male or female, between the ages of 18 and 75 inclusive, who are motivated to stop smoking.
•Score 7 or higher on the Contemplation Ladder at the Screening, Week -1, and Baseline Visits.

Exclusion Criteria

•PANSS score \>70 at Screen or Baseline Visit.
•Subjects hospitalized within the past six months due to suicidal ideation or suicidal behavior or subjects considered to have serious suicidal ideation or suicidal behavior within the past six moth.
•Subjects having active suicidal ideation or behavior identified at Screen, Week -1, or Baseline Visit.
•Subjects taking Bupropion.

Related studies

Phone Enabled Implementation of Cessation Support

NCT05628389 · Smoking Cessation

Clinical Research Evaluating Smoking Cessation With E-Cigarettes and Nicotine Therapy

NCT06948058 · Smoking Cessation, Obesity and Obesity-related Medical Conditions

RECRUITINGPhase 2/3

Empowering Cessation ACS South Region

NCT06820034 · Smoking Cessation

Trauma-Informed Care for Smoking Cessation for Pregnancy

NCT07129590 · Smoking Cessation, Tobacco Smoking, and more

RECRUITINGPhase 4

Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care

NCT06598397 · Human Immunodeficiency Virus (HIV), Smoking Cessation

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 15, 2011Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment128

Start dateMay 2008

Last updatedApr 15, 2011

Condition

Smoking Cessation

Locations shown

Pfizer Investigational Site

Aurora, Colorado

Pfizer Investigational Site

Farmington, Connecticut

Pfizer Investigational Site

New Haven, Connecticut

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 15, 2011Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions